Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : MTX-23
Catalog No.: PC-21124Not For Human Use, Lab Use Only.
MTX-23 is a proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) splice variant-7 (AR-V7) and AR-full length (AR-FL) with DC50 of 0.37 and 2 uM, respectively.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
MTX-23 is a proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) splice variant-7 (AR-V7) and AR-full length (AR-FL) with DC50 of 0.37 and 2 uM, respectively.
MTX-23 simultaneously binds AR's DNA binding domain (DBD) and the Von Hippel-Lindau (VHL) E3 ubiquitin ligase.
MTX-23 inhibits prostate cancer cellular proliferation and increased apoptosis only in androgen-responsive prostate cancer cells.
MTX-23 (1 uM) stimulates apoptosis in 22Rv1 cells, induces poly-ubiquitination of AR-V7 and AR-FL.
MTX-23 is effective against SAT-resistant prostate cancer cell lines, inhibits enzalutamide-resistant prostate cancer growth in mice.
| M.Wt | 882.06 | |
| Formula | C43H53F2N7O7S2 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Geun Taek Lee, et al. Mol Cancer Ther. 2021 Mar;20(3):490-499.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
